Pediatric neurologist Dr. Carlos G. Aguirre-Velazquez has released continuing results from his clinical study involving the use of CBD oil for seizures relating to tuberous sclerosis complex (TSC). Dr. Aguirre measured the frequency, intensity, and duration of convulsive crises in TSC patient, as well as studied their quality of life, use of prescription drugs, and the long-term sustainability of CBD treatment. The results of his study are positive, with 60% of participants exhibiting clinically significant (60-80%) reductions in the frequency of their seizures with the use of CBD products. Additionally, patients using CBD experienced an improvement in mood, appetite, cognition, and overall quality of life, without experiencing adverse side effects, suggesting CBD can be used consistently while maintaining a high safety profile. Minor side effects like drowsiness and appetite increase existed, but they could improve or dissipate with adjusted doses. Researchers explained, “The experience of parents and patients with medicinal cannabis (CBD), as reported in our survey, suggests that CBD reduced the frequency, intensity, and duration of convulsive crises secondary to TSC.”
This information has been provided by Medical Marijuana Inc. and approved by our Chief Medical Officer.